EyeGene Financials
| 185490 Stock | KRW 2,825 5.00 0.18% |
EyeGene |
Understanding current and past EyeGene Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of EyeGene's financial statements are interrelated, with each one affecting the others. For example, an increase in EyeGene's assets may result in an increase in income on the income statement.
Please note, the presentation of EyeGene's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, EyeGene's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of EyeGene's management manipulating its earnings.
EyeGene Stock Summary
EyeGene competes with CJ Seafood, Chorokbaem Healthcare, Shinsegae Food, InnoTherapy, and Osang Healthcare. EyeGene Inc., a biotechnology company, engages in the research and development of biopharmaceutical drugs for the treatment and prevention of age-related diseases in South Korea. EyeGene Inc. was founded in 2000 and is headquartered in Seoul, South Korea. Eyegene is traded on Korean Securities Dealers Automated Quotations in South Korea.| Instrument | Korea Stock View All |
| Exchange | KOSDAQ |
| ISIN | KR7185490000 |
| Business Address | B-910, 401, Yangcheon-ro, |
| Industry | Biotechnology |
| Benchmark | Dow Jones Industrial |
| Website | www.eyegene.co.kr |
| Phone | 82 2 322 1687 |
| Currency | KRW - South Korean Won |
You should never invest in EyeGene without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of EyeGene Stock, because this is throwing your money away. Analyzing the key information contained in EyeGene's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
EyeGene Key Financial Ratios
EyeGene's financial ratios allow both analysts and investors to convert raw data from EyeGene's financial statements into concise, actionable information that can be used to evaluate the performance of EyeGene over time and compare it to other companies across industries.| Return On Equity | -51.2 | |||
| Return On Asset | -0.19 | |||
| Number Of Employees | 63 | |||
| Beta | 0.56 | |||
| Z Score | 61.2 |
EyeGene Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining EyeGene's current stock value. Our valuation model uses many indicators to compare EyeGene value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across EyeGene competition to find correlations between indicators driving EyeGene's intrinsic value. More Info.EyeGene is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value EyeGene by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for EyeGene's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.EyeGene Systematic Risk
EyeGene's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. EyeGene volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was ten with a total number of output elements of fifty-one. The Beta measures systematic risk based on how returns on EyeGene correlated with the market. If Beta is less than 0 EyeGene generally moves in the opposite direction as compared to the market. If EyeGene Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one EyeGene is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of EyeGene is generally in the same direction as the market. If Beta > 1 EyeGene moves generally in the same direction as, but more than the movement of the benchmark.
EyeGene December 1, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of EyeGene help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of EyeGene. We use our internally-developed statistical techniques to arrive at the intrinsic value of EyeGene based on widely used predictive technical indicators. In general, we focus on analyzing EyeGene Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build EyeGene's daily price indicators and compare them against related drivers.
| Information Ratio | (0.23) | |||
| Maximum Drawdown | 13.42 | |||
| Value At Risk | (4.14) | |||
| Potential Upside | 4.69 |
Complementary Tools for EyeGene Stock analysis
When running EyeGene's price analysis, check to measure EyeGene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy EyeGene is operating at the current time. Most of EyeGene's value examination focuses on studying past and present price action to predict the probability of EyeGene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move EyeGene's price. Additionally, you may evaluate how the addition of EyeGene to your portfolios can decrease your overall portfolio volatility.
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Stocks Directory Find actively traded stocks across global markets | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios |